Wells Fargo & Company Anebulo Pharmaceuticals, Inc. Transaction History

Wells Fargo & Company

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$2.34 - $3.0 $2 - $3	1 Added 1.64%	62 $0
Q4 2023 Feb 09, 2024	BUY	$1.71 - $3.17 $5 - $9	3 Added 5.17%	61 $0
Q3 2023 Nov 13, 2023	BUY	$2.15 - $3.49 $2 - $3	1 Added 1.75%	58 $0
Q2 2023 Aug 15, 2023	BUY	$2.06 - $2.98 $4 - $5	2 Added 3.64%	57 $0
Q1 2023 May 12, 2023	BUY	$2.27 - $3.25 $2 - $3	1 Added 1.85%	55 $0
Q4 2022 Feb 13, 2023	BUY	$1.79 - $3.39 $30 - $57	17 Added 45.95%	54 $0
Q3 2022 Nov 14, 2022	BUY	$2.8 - $5.49 $47 - $93	17 Added 85.0%	37 $0
Q2 2022 Aug 12, 2022	BUY	$2.7 - $7.15 $2 - $7	1 Added 5.26%	20 $0
Q2 2021 Aug 16, 2021	BUY	$6.58 - $8.95 $125 - $170	19 New	19 $0

7.34M

Ticker ANEB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,633,200
Market Cap $41.5M
Description
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The ...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.